Abstract
The ability of polyvinylpyrrolidone to decrease mutagenic effects of some anticancer drugs (fotrine and fopurine) has been demonstrated in mammals. The reduction of mutagenic effects of these chemicals by combination with polyvinylpyrrolidone has been discovered in a dominant lethal test, in a sperm abnormality test and in cytogenetic analysis in bone marrow cells from mammals. The diminution of mutagenicity is pronounced with use of higher doses of the chemicals.
The modification ability of any residual substance must be taken into consideration in estimation of genetic hazard.
This is a preview of subscription content, log in via an institution to check access.
Access this chapter
Tax calculation will be finalised at checkout
Purchases are for personal use only
References
Revazova, J. A., Radchenko, L. U.: Induction of dominant lethals Fotrine in mice (in Russian). Genetika XII, 2, 165–167 (1976)
Revazova, J. A., Radchenko, L. U.: Modifying action of polyvinylpyrrolidone on the mutagenic activity of Fotrine (in Russian). Chem.-Pharm. J. 9, 11–15 (1976)
Author information
Authors and Affiliations
Editor information
Editors and Affiliations
Rights and permissions
Copyright information
© 1980 Springer-Verlag
About this paper
Cite this paper
Revazova, J., Radchenko, L., Muravnik, G. (1980). Modification of Mutagenic Activity of Anticancer Drugs. In: Chambers, P.L., Klinger, W. (eds) Further Studies in the Assessment of Toxic Actions. Archives of Toxicology, vol 4. Springer, Berlin, Heidelberg. https://doi.org/10.1007/978-3-642-67729-8_15
Download citation
DOI: https://doi.org/10.1007/978-3-642-67729-8_15
Publisher Name: Springer, Berlin, Heidelberg
Print ISBN: 978-3-540-10191-8
Online ISBN: 978-3-642-67729-8
eBook Packages: Springer Book Archive